Presa d’atto contratto. Autorizzazione alla conduzione della Sperimentazione: “Reduced-dosed rivaroxaban and standard –dosed rivaroxaban versus ASA in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism. The Einstein Choice Study”. Numero EudraCT 2013-000619-26. Codice: BAY 59-7939/16416.